BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights

  Fibrocell will also host a conference call and webcast at 8:30 a.m. EST on the same day to discuss its financial results and operational highlights.

  November 6, 2017

   · 

  1 min read
• Business

  Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical Officer

  Dr. Lawrence will report to William Lis, chief executive officer, and will be responsible for leading all product development, as well as clinical strategies.

  November 6, 2017

   · 

  2 min read
• Business

  Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance

  Total revenues of $2.29B, down 2% compared to the prior year period

  November 6, 2017

   · 

  37 min read
• 5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration

  The International mRNA Health Conference, the premier meeting destination for professionals and academics in the field of mRNA drugs, celebrated the success of its 5th annual event held in Berlin, Germany on November 1–2.

  November 6, 2017

   · 

  2 min read
• Policy

  Collegium Notified that the FDA Will Not Meet PDUFA Goal Date for sNDA for Xtampza ER

  Collegium CEO says the FDA hasn’t requested any additional scientific information or data.

  November 6, 2017

   · 

  8 min read
• Drug Development

  Lupus Research Alliance Prompted Stelara Study for Lupus - Results Show Potential for New Treatment Option

  Based on the positive results from the Phase II study, Janssen announced plans to test Stelara in a future Phase III program.

  November 6, 2017

   · 

  3 min read
• Pharm Country

  ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) Program

  As a result, the company expects to receive approximately $1.6 million of net cash proceeds prior to the end of 2017.

  November 6, 2017

   · 

  3 min read